| Relationship between biomarkers and subsequent clinical and angiographic restenosis after paclitaxel-eluting stents for treatment of STEMI: a HORIZONS-AMI substudy. | |
| | |
MedLine Citation:
|
PMID: 22466810 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Drug-eluting stents (DES) reduce the incidence of in-stent restenosis (ISR) after primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI). Whether the use of biomarkers might be of utility to identify patients who remain at risk for DES ISR after primary PCI has never been examined. A total of 26 biomarkers were measured at enrollment and 30 days and analyzed at a central core laboratory in 501 STEMI patients from the HORIZONS-AMI trial. All patients underwent primary PCI with the TAXUS paclitaxel-eluting stent (PES), were scheduled for routine angiographic follow-up at 13 months, and were followed for 3 years. Mean in-stent late-loss was 0.28 ± 0.57 mm, and target lesion revascularization (TLR) at 3 years occurred in 9.1 % of patients. Low levels of interleukin-6 (IL-6) and placental growth factor (PLGF) at admission were associated with both higher in-stent late loss and ischemia-driven TLR. Additionally, low admission levels of cardiotrophin-1 (CT-1) were associated with higher rates of ischemia-driven TLR. At 30-day follow-up lower values of IL-1ra (IL-1ra), matrix metalloproteinase 9 (MMP9), and myeloperoxidase (MPO), and a decline relative to admission in IL-1ra, monocyte chemotactic protein-1 (MCP-1), and MMP9 were associated with higher in-stent late loss. Low values of IL-6 at 30 days were also associated with ischemia-driven TLR. After multivariate adjustment, only MPO at 30 days and a decline of MCP-1 between admission and 30 days were associated with in-stent late loss, and only CT-1 was associated with TLR. MPO at 30 days and a decline of MCP-1 between admission and 30 days were independently associated with in-stent late loss, and CT-1 was associated with TLR. Additional studies to confirm and validate the utility of these biomarkers are warranted. |
| | |
Authors:
|
Bimmer E Claessen; Gregg W Stone; Roxana Mehran; Bernhard Witzenbichler; Bruce R Brodie; Jochen Wöhrle; Adam Witkowski; Giulio Guagliumi; Krzysztof Zmudka; José Ps Henriques; Jan Gp Tijssen; Elias A Sanidas; Vasiliki Chantziara; Diaa Hakim; Selene Leon; Ke Xu; George D Dangas |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-4-1 |
Journal Detail:
|
Title: Journal of thrombosis and thrombolysis Volume: - ISSN: 1573-742X ISO Abbreviation: - Publication Date: 2012 Apr |
Date Detail:
|
Created Date: 2012-4-2 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9502018 Medline TA: J Thromb Thrombolysis Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Cardiovascular Research Foundation, New York, NY, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Pressure effects on the magnetic behaviour of copper (II) compounds: magnetic ordering of layered or...
Next Document: Platelet glycoprotein IIIA PIA2 polymorphism is associated with ST elevation acute myocardial infarc...